Pharmacogenetic testing, which is used to classify how patients with major depressive disorder (MDD) metabolize medications, reduces adverse drug-gene interactions, new research shows. In a randomized ...

Patients with MDD exhibit significantly higher triglyceride levels, which correlate with worse functional impairment scores.

Most antidepressants are metabolized through the cytochrome P (CYP) 450 pathway; therefore, most drug metabolism genes on pharmacogenetic testing panels are related to CYP450 oxidase enzyme subunits.

Anti-inflammatory therapies that are highly effective for inflammatory skin diseases might also be relevant to depression ...

Myriad Genetics, Inc., a leader in molecular diagnostic testing and precision medicine, today announced the publication of a new meta-analysis of six prospective controlled studies that included 3,532 ...

Myriad Genetics, Inc. announced that a study published in the Journal of Clinical Psychopharmacology found that the GeneSight® Psychotropic Test significantly reduced psychiatric hospitalizations in ...

Papakostas G.I., Shelton R.C., Kinrys G., Henry M.E., Bakow B.R., Lipkin S.H., Pi B., Thurmond L., Bilello J.A. Assessment of a multi-assay, serum-based biological ...

Depression-related fatigue is caused by cellular "overworking" at rest and a failure to produce energy under stress.